11 results about "Hydrobromide" patented technology

The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosylate, and the like.

This application discloses an analytical method for N-nitrosamine vortioxetine in vortioxetine hydrobromide tablets, belonging to the field of pharmaceutical impurity analysis. The method employs high-performance liquid chromatography (HPLC), with the following chromatographic conditions: a 4.6 mm × 250 mm column packed with octadecylsilane-bonded silica gel, with a particle size of 5 μm; mobile phase A is a 90:10 water-acetonitrile mixture containing 0.025%–0.035% trifluoroacetic acid (v / v); mobile phase B is acetonitrile; gradient elution; column temperature 38–42 °C; flow rate 0.9–1.1 ml / min; injection volume 50 μl; and detection wavelength 226 nm. This analytical method effectively eliminates excipient interference and exhibits excellent detection performance (specificity, sensitivity, linearity, precision, accuracy, and robustness), accurately detecting the content of N-nitrosamine vortioxetine in vortioxetine hydrobromide tablets, meeting quality control requirements.

Novel crystalline forms of Nirogacestat dihydrobromide and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing γ-secretase inhibitor drugs and drugs for treating desmoid tumors.

The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosylate, and the like.

The application discloses a kind of wet etching liquid and etching method for InP-based disc microcavity, the etching liquid is made of hydrobromic acid, hydrochloric acid, hydrogen peroxide and deionized water is mixed, the etching liquid is placed under light shielding condition after preparation 4~8 hours.The etching method is to use the etching liquid and carry out etching under light shielding condition.The etching liquid is placed under light shielding condition after preparation, and the purpose is to make the microcosmic mass transfer of solution system after mixing and initial reaction reach equilibrium, eliminate the fluctuation caused by temporary concentration gradient, ensure the initial kinetic state of each etching is consistent.The application breaks through the traditional technical prejudice that "wet etching does not need to strictly avoid light", and first clearly establishes "full light shielding" as the key process variable to realize and lock the ideal etching morphology of InP-based microcavity, and cooperates with specific ratio to form a complete, stable and predictable process system.The discovery provides a new control dimension and theoretical basis for wet etching process.

The present application provides a salt of a triazine compound having an inhibitory action against aldosterone synthase, which is useful as a medicine, particularly a prophylactic or therapeutic agent for primary aldosteronism and the like, a crystal thereof, and a production method thereof. Specifically, the present application provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetylamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is a hydrobromide, a sulfate, a succinate, or a p-toluenesulfonate, or the like.

The application belongs to the technical field of chemical synthesis, and specifically provides a preparation method of N-[4,6-bis(heptadecyloxy)-1,3,5-triazinyl-2-yl]hexane-1,6-diamine, which comprises the following steps: S1, performing ether exchange reaction of 2-chloro-4,6-dimethoxy-1,3,5-triazine and 9-heptadecanol to generate 2-chloro-4,6-bis(heptadecyloxy)-1,3,5-triazine; S2, performing reaction of the 2-chloro-4,6-bis(heptadecyloxy)-1,3,5-triazine and an ammoniating reagent to generate 4,6-bis(heptadecyloxy)-1,3,5-triazin-2-amine; and S3, performing nucleophilic substitution reaction of the 4,6-bis(heptadecyloxy)-1,3,5-triazin-2-amine and 6-bromohexylamine hydrobromide to generate N-[4,6-bis(heptadecyloxy)-1,3,5-triazinyl-2-yl]hexane-1,6-diamine. According to the preparation method of the embodiment of the application, the reaction is mild, the selectivity is high, the yield is high, the by-products are few, the generated three wastes are few, and the route is feasible.

The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosylate, and the like.

The application belongs to the technical field of flame retardants, and particularly relates to a melamine hydrobromide flame retardant and a preparation method thereof. The flame retardant has a core-shell structure, the inner core is hydroxylated melamine hydrobromide surface-modified by a silane coupling agent, and the outer shell is a melamine resin synergistically enhanced by ammonium polyphosphate and oxidized cellulose nanofilament. The interface combination of the core-shell is strengthened through silanization treatment, and the spatial and temporal synergy of gas phase and condensed phase flame retardation is realized by using the composite shell. The obtained flame retardant has high thermal stability in a polymer matrix, can significantly improve the limiting oxygen index of the composite material after being added, and passes the UL-94 V-0 level test, and has a wide application prospect in the field of high polymer material flame retardation.

The present invention relates to the field of pharmaceuticals, and in particular, to a salt form of a pyridazine derivative, a crystal form, a method for preparing same, and use thereof. The present invention provides a salt form of a compound of formula I, and particularly relates to a hydrochloride salt, a hydrobromide salt, a sulfate salt, a phosphate salt, an oxalate salt, a citrate salt, a malate salt, a maleate salt, a fumarate salt, a succinate salt, a malonate salt, a methanesulfonate salt, a benzenesulfonate salt, and a p-toluenesulfonate salt. The present invention further provides an amorphous form and a crystal form of the hydrochloride salt, and particularly relates to crystal form A and crystal form B. The present invention further provides a method for preparing the salt form and the crystal form, and use thereof. The salt form of the compound of formula I and the crystal form of the present invention have significant SOS1 inhibitory activity and a significant anti-tumor cell proliferation effect, have advantageous pharmaceutical properties such as high solubility, good stability, and excellent pharmacokinetics, and are thus suitable for pharmaceutical use.